Bellevue Group Ag Castle Biosciences Inc Transaction History

Bellevue Group Ag

$5.93 Billion
Q3 2024

A detailed history of Bellevue Group Ag transactions in Castle Biosciences Inc stock. As of the latest transaction made, Bellevue Group Ag holds 1,262,030 shares of CSTL stock, worth $35.5 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares

1,262,030

Previous 1,217,101 3.69%

Holding current value

$35.5 Million

Previous $26.5 Million 35.84%

% of portfolio

0.61%

Previous 0.44%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$17.4 - $31.47 $781,764 - $1.41 Million	44,929 Added 3.69%	1,262,030 $36 Million
Q2 2024 Aug 14, 2024	SELL	$18.84 - $24.94 $56,218 - $74,420	-2,984 Reduced 0.24%	1,217,101 $26.5 Million
Q1 2024 May 15, 2024	SELL	$18.06 - $25.3 $222,011 - $311,012	-12,293 Reduced 1.0%	1,220,085 $27 Million
Q4 2023 Feb 14, 2024	BUY	$12.19 - $22.43 $52,989 - $97,503	4,347 Added 0.35%	1,232,378 $26.6 Million
Q3 2023 Nov 14, 2023	BUY	$13.28 - $20.3 $1.38 Million - $2.11 Million	103,988 Added 9.25%	1,228,031 $20.7 Million
Q2 2023 Aug 14, 2023	BUY	$11.66 - $26.0 $2.04 Million - $4.55 Million	175,165 Added 18.46%	1,124,043 $15.4 Million
Q1 2023 May 15, 2023	BUY	$19.47 - $28.49 $88,900 - $130,085	4,566 Added 0.48%	948,878 $21.6 Million
Q4 2022 Feb 14, 2023	BUY	$18.08 - $30.0 $44,133 - $73,230	2,441 Added 0.26%	944,312 $22.2 Million
Q3 2022 Nov 14, 2022	BUY	$22.51 - $34.32 $18,278 - $27,867	812 Added 0.09%	941,871 $24.6 Million
Q2 2022 Aug 11, 2022	BUY	$16.0 - $45.99 $5.34 Million - $15.3 Million	333,445 Added 54.88%	941,059 $20.7 Million
Q1 2022 May 13, 2022	BUY	$33.17 - $46.98 $20.2 Million - $28.5 Million	607,614 New	607,614 $27.3 Million

Others Institutions Holding CSTL

# of Institutions

202

Shares Held

26M

Call Options Held

303K

Put Options Held

30.3K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $739M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Castle Biosciences Inc Transaction History